A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

This study tests a new drug called PCS6422 combined with capecitabine (an oral chemotherapy tablet) in people with advanced or metastatic breast cancer. It targets patients whose cancer has stopped responding to other standard treatments like taxanes or anthracyclines. **You may be eligible if:** - You are 18 or older - You have advanced or metastatic breast cancer that is either triple-negative, or hormone receptor positive/HER2 negative - Your cancer cannot be surgically removed - Other standard treatments are no longer working or are not suitable for you - You are in good general health (ECOG score 0 or 1) with at least 24 weeks life expectancy - Your organ function (bone marrow, liver, kidney) is adequate **You may NOT be eligible if:** - You are currently able to receive taxanes or anthracycline-based chemotherapy - You have untreated or actively progressing brain metastases - Your organ function does not meet required levels - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.